GH Research Raises $125 Million to Fund DMT Treatment for Depression
GH Research closed a $125 million Series B financing round to fund the advancement of its 5-MeO-DMT treatment.
Entries by Jennifer Walker-Journey
First-Ever Jewish Psychedelic Summit Planned for May 2-3
The first conference of its kind, the Jewish Psychedelic Summit, will explore the connection between psychedelics and Judaism.
Silo Wellness Expands Shareholder Base to Europe
Toronto’s Silo Wellness is now trading on the German Stock Exchange as demand for psychedelic treatments expands.
Daniel Carcillo’s Psychedelic Startup Wesana Health Raises More Funds, On Track to Go Public
Former NHL player Daniel Carcillo’s psychedelic startup Wesana Health is preparing to take the company public.
Ketamine Therapy Shows Benefits in Treating Depression Related to Childhood Abuse
Adults with depression who were abused or neglected as children responded better to intravenous ketamine therapy than depressed adults who were not mistreated, according to a poster presentation and discussion at the recent Anxiety and Depression Association of America 2021 Virtual Conference. The study involved 189 adults with treatment-resistant depression, each of whom underwent at […]
Psychedelics Company Atai Adds Brain-Computer Interface for Mental Health Treatment
Atai Life Sciences is working to combine psychedelics with brain-computer interfaces for mental health treatment.
Psychedelic Business News Spotlight: April 9, 2021
This week in psychedelic business news: a psilocybin delivery system for brain inflammation, a genetic test to predict your psychedelic-assisted therapy experience, and a potential first treatment for a debilitating form of schizophrenia.
Psychedelic Conference to Explore Promising Therapies for Veterans, First Responders
The Heroic Dose conference will explore the use of psychedelic therapies to treat post-traumatic stress disorder, substance abuse, and suicide among military veterans and first responders.
Mydecine Prepares to Present Four Novel Psychedelic Candidates
Colorado-based Mydecine is launching four new psychedelic candidates for use in treating conditions like anxiety and depression.
Yale to Study Psilocybin for Cluster Headaches
Psilocybin is showing relief as treatment for cluster headaches — a painful condition that affects more than 300,000 Americans a year.
